Physical performance measures for predicting outcome in cancer patients: a systematic review

Verweij, Norbert M.; Schiphorst, A. H. W.; Pronk, Apollo; Bos, Frederiek van den; Hamaker, Marije E.

doi:10.1080/0284186x.2016.1219047

Cited by 126 publications

(111 citation statements)

References 42 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Moreover, and to the best of our knowledge no studies have compared performance-based to self-report measures among patients with cancer to identify the best predictive measures for functional decline 34 although one study has compared the utility of different self-report and physical performance measures to predict mortality, the most extreme manifestation of functional decline. Among 200 women 65 years of age and older with gynecological cancers, Cesari M, et al, 35 compared six measures which included the VES-13, usual gait speed, SPPB, grip strength, ECOG Performance Status Scale, Karnofsky Performance Status Scale, ADL and IADL on their abilities to predict one-year mortality.…”

Section: Discussionmentioning

confidence: 99%

Short Physical Performance Battery, usual gait speed, grip strength and Vulnerable Elders Survey each predict functional decline among older women with breast cancer

Owusu

Margevicius

Schluchter

et al. 2017

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Objective To determine the ability of three performance-based measures [Short Physical Performance Battery (SPPB), gait speed, and Grip Strength] and a self-report measure [Vulnerable Elders Survey (VES-13)] to predict functional decline among older women with breast cancer. Patients and Methods Longitudinal data from a study of women ≥ 65 years, with newly diagnosed stage I–III breast cancer, recruited from ambulatory oncology clinics between July 2010 and April 2014, was used. The primary outcome was functional decline, Yes or No, defined as a decrease in ≥ 1-point from baseline to 12 months, on Activities of Daily Living Scales. Multivariable logistic regression and Receiver Operator Curve analyses were conducted Results Among 123 participants 18 (15%) developed functional decline. The predictive abilities for measures were: SPPB [Adjusted odds ratio (AOR) = 1.65 per unit decrease in scores, 95% confidence interval (CI) =1.33–2.05; area under the receiver operator curve (AUC) = 0.93; sensitivity=94%, specificity=80%]; gait speed (AOR = 1.76 per unit increase in usual walking time, CI=1.29–2.41; AUC=0.93; sensitivity=87%, specificity=79%); VES-13 (AOR = 1.64 per unit increase in scores, CI=1.31–2.05; AUC=0.87; sensitivity=83%, specificity=84%); and grip strength: (AOR = 1.18 per unit decrease in grip strength, CI=1.06–1.30; AUC=0.80; sensitivity=67%, specificity=77%). Conclusion SPPB, gait speed, grip strength and VES-13 all demonstrated excellent predictive abilities for functional decline. Larger studies are warranted to confirm the utility of these measures for identifying older adults with cancer at increased risk for functional decline, who may then be targeted for studies to explore the effects of interventions to improve function.

show abstract

Section: Discussionmentioning

confidence: 99%

Short Physical Performance Battery, usual gait speed, grip strength and Vulnerable Elders Survey each predict functional decline among older women with breast cancer

Owusu

Margevicius

Schluchter

et al. 2017

Journal of Geriatric Oncology

View full text Add to dashboard Cite

show abstract

“…Prior to the first chemotherapy infusion (study baseline), research staff assessed the physical function of the participants using 2 measures: the Timed Up and Go test 25,26 and the Short Physical Performance Battery. 27,28 Additional patient-reported measures At baseline, study participants completed questionnaires for patient-reported measures of function and quality Cancer September 1, 2019 of life: the patient-reported Karnofsky performance status, 29 Medical Outcomes Survey (MOS) of physical function, 30 Functional Assessment of Cancer Therapy-General (FACT-G; version 4), 31 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F; version 4), 32 and Mental Health Index-13 (MHI-13).…”

Section: Research Staff-assessed Physical Functionmentioning

confidence: 99%

Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice

Nyrop

Deal

Reeder-Hayes

et al. 2019

Cancer

View full text Add to dashboard Cite

BACKGROUND: In the current study, the authors investigated the incidence of moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) for chemotherapy regimens commonly used in current clinical practice for the treatment of patients with early breast cancer. Patient-reported and clinician-assessed CIPN severity scores were compared, and risk factors for CIPN severity were identified. METHODS: Patients completed a Patient-Reported Symptom Monitoring form and oncologists completed a Common Terminology Criteria for Adverse Events form. CIPN reports were collected prospectively during regularly scheduled infusion visits throughout the duration of chemotherapy. RESULTS: The sample included 184 women with a mean age of 55 years; approximately 73% were white. The 4 chemotherapy regimens used were doxorubicin and cyclophosphamide plus paclitaxel (60 patients); docetaxel and cyclophosphamide (50 patients); docetaxel, carboplatin, and anti-human epidermal growth factor receptor 2 (HER2) (24 patients); and doxorubicin and cyclophosphamide plus paclitaxel and carboplatin (18 patients). All patients treated with doxorubicin and cyclophosphamide plus paclitaxel and doxorubicin and cyclophosphamide plus paclitaxel and carboplatin received paclitaxel; all patients treated with docetaxel and cyclophosphamide and docetaxel, carboplatin, and anti-HER2 received docetaxel. The chemotherapy dose was reduced in 52 patients (28%); in 15 patients (29%), this reduction was due to CIPN. Chemotherapy was discontinued in 26 patients (14%), 8 because of CIPN. Agreement between patient-reported and clinician-assessed CIPN severity scores was minimal (weighted Cohen kappa, P = .34). Patient-reported moderate to severe CIPN was higher for paclitaxel (50%) compared with docetaxel (17.7%) (P < .001). Pretreatment arthritis and/or rheumatism (relative risk [RR], 1.58; 95% CI, 1.06-2.35 [P = .023]) and regimens containing paclitaxel (RR, 2.88; 95% CI, 1.72-4.83 [P < .0001]) were associated with higher CIPN severity. Being married (RR, 0.57; 95% CI, 0.37-0.887 [P = .01]) was found to be associated with lower CIPN severity. CONCLUSIONS: The discrepancy between patient-reported and clinician-assessed CIPN underscores the need for both patient and clinician perspectives regarding this common, dose-limiting, and potentially disabling side effect of chemotherapy. Cancer 2019;125:2945-2954.

show abstract

“…Prior work showed that in younger patients with cancer, high symptom burden can negatively affect physical function, quality of life, and survival . Impaired physical function was shown to predict worse outcomes such as higher mortality and lower quality of life in community‐dwelling older adults as well as in individuals with cancer …”

mentioning

confidence: 99%

Association Between Symptom Burden and Physical Function in Older Patients with Cancer

Pandya

Magnuson

Flannery

et al. 2019

J American Geriatrics Society

View full text Add to dashboard Cite

OBJECTIVES To evaluate the independent association between symptom burden and physical function impairment in older adults with cancer. DESIGN Cross‐sectional. SETTING Two university‐based geriatric oncology clinics. PARTICIPANTS Patients with cancer aged 65 years or older who underwent evaluation with geriatric assessment (GA). MEASUREMENTS Symptom burden was measured as a summary score of severity ratings (range = 0‐10) of 10 commonly reported symptoms using a Clinical Symptom Inventory (CSI). Functional impairment was defined as the presence of one or more impairments of instrumental activities of daily living (IADLs), any significant physical activity limitation on the Medical Outcomes Survey (MOS), one or more recent falls in the previous 6 months, or a Short Physical Performance Battery (SPPB) score of 9 or less. Multivariate analysis evaluated the association between symptom burden and physical function impairment, adjusting for other clinical and sociodemographic variables. RESULTS From 2011 to 2015, 359 patients with cancer and a median age of 81 years (range = 65‐95 y) consented. The mean CSI score was 23.2 ± 20.5 with an observed range of 0 to 90. Patients in the highest quartile of symptom burden (N = 91; CSI score 52 ± 13) had a higher prevalence of IADL impairment (91% vs 51%), physical activity limitation (93% vs 65%), falls (55% vs 21%), and SPPB score of 9 or less (92% vs 69%) (all P values <.01) when compared with those in the bottom quartile (N = 81; CSI score: 2 ± 2). With each unit increase in CSI score, the odds of having IADL impairment, physical activity limitations, falls, and SPPB scores of 9 or less increased by 4.8%, 4.4%, 2.9%, and 2.5%, respectively (P < .05 for all results). CONCLUSIONS In older patients with cancer, higher symptom burden is associated with functional impairment. Future studies are warranted to evaluate if improved symptom management can improve function in older cancer patients. J Am Geriatr Soc 67:998–1004, 2019.

show abstract

Physical performance measures for predicting outcome in cancer patients: a systematic review

Cited by 126 publications

References 42 publications

Short Physical Performance Battery, usual gait speed, grip strength and Vulnerable Elders Survey each predict functional decline among older women with breast cancer

Short Physical Performance Battery, usual gait speed, grip strength and Vulnerable Elders Survey each predict functional decline among older women with breast cancer

Patient‐reported and clinician‐reported chemotherapy‐induced peripheral neuropathy in patients with early breast cancer: Current clinical practice

Association Between Symptom Burden and Physical Function in Older Patients with Cancer

Contact Info

Product

Resources

About